INDICATIONS
COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.
COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION
CONTRAINdications
COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients.

Please see additional Important Safety Information on pages 2-4. Click here for full Prescribing Information, including Medication Guide.
For PsA patients with coexistent moderate to severe plaque psoriasis:
300 mg once a week for the first 5 weeks, monthly thereafter

**Monthly maintenance dosing***

- Each 300-mg dose is given as 2 subcutaneous injections of 150 mg\(^1\)

**For other PsA patients:**
- Recommended dose of 150 mg
- Administer with or without a loading dose
- COSENTYX may be administered with or without methotrexate
- If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg

*Monthly maintenance dose=1 dose every 4 weeks.

\(^1\)The first self-injection should be performed under the supervision of a qualified healthcare professional. Patients should be trained in proper injection technique prior to self-administration.

\(^2\)For some patients, a dose of 150 mg may be acceptable.

PsA=psoriatic arthritis.

**IMPORTANT SAFETY INFORMATION (cont)**

**WARNINGS AND PRECAUTIONS**

**Infections**

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in subjects treated with COSENTYX compared to placebo-treated subjects. In placebo-controlled clinical trials in patients with moderate to severe plaque psoriasis, higher rates of common infections such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%), and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in patients with psoriatic arthritis and ankylosing spondylitis. The incidence of some types of infections appeared to be dose-dependent in clinical studies.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Please see additional Important Safety Information on pages 1, 3, and 4.

[Click here](#) for full Prescribing Information, including Medication Guide.
For AS patients:
150 mg once a week for the first 5 weeks, monthly thereafter

<table>
<thead>
<tr>
<th>Initial loading†</th>
<th>Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Once weekly x 5 weeks</td>
<td>Once monthly</td>
</tr>
</tbody>
</table>

Administer with or without a loading dosage.

*Monthly maintenance dose=1 dose every 4 weeks.
†The first self-injection should be performed under the supervision of a qualified healthcare professional. Patients should be trained in proper injection technique prior to self-administration.

AS=ankylosing spondylitis.

**IMPORTANT SAFETY INFORMATION (cont)**

**Infections (cont)**

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and COSENTYX should be discontinued until the infection resolves.

**Pre-treatment Evaluation for Tuberculosis**

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Do not administer COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving COSENTYX should be monitored closely for signs and symptoms of active TB during and after treatment.

**Inflammatory Bowel Disease**

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in patients treated with COSENTYX during clinical trials in plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory study in 59 patients with active Crohn's disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.

Please see additional Important Safety Information on pages 1, 2, and 4.

Click here for full Prescribing Information, including Medication Guide.
The FIRST AND ONLY FULLY HUMAN IL-17A antagonist
FOR PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS

How supplied: COSENTYX is available in Sensoready® pens

- Each Sensoready pen contains 150 mg/mL of COSENTYX*
  - Each 300-mg/mL package contains two 150-mg/mL Sensoready pens
  - Each 150-mg/mL package contains one 150-mg/mL Sensoready pen
- Prefilled syringes are also available—each contains 150 mg/mL*

*The removable cap of the COSENTYX Sensoready pen and the prefilled syringe contains natural rubber latex and should not be handled by latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Learn more at CosentyxHCP.com

IMPORTANT SAFETY INFORMATION (cont)

Hypersensitivity Reactions
Anaphylaxis and cases of urticaria occurred in patients treated with COSENTYX in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable cap of the COSENTYX Sensoready® pen and the COSENTYX prefilled syringe contains natural rubber latex which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Vaccinations
Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. Patients treated with COSENTYX should not receive live vaccines.

Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.

MOST COMMON ADVERSE REACTIONS
Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see additional Important Safety Information on pages 1-3. Click here for full Prescribing Information, including Medication Guide.